| Subject: | FDA Notifies Healthcare Professionals with Regard to Natrecor (Nesiritide), Mifeprex (Mifepristone), Raptiva (Efalizumab) |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Wed, 10 Aug 2005 - 10:00 am |
| Audience: Cardiologists/cardiovascular healthcare professionals
The FDA has published recommendations of an expert panel of cardiology and heart failure clinicians with regard to Natrecor (nesiritide). Natrecor is indicated for the intravenous treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity. With respect to recent questions raised about worsened renal function and mortality, the panel made the following specific,... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
Related MCN Products:
|
|
StayAlert! notifies healthcare customers of all federal and regulatory body legislation changes impacting the healthcare industry, including TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others. StayAlert! complements this with regulatory implementation action plans. StayAlert! serves as a virtual healthcare department, augmenting traditional employee staffed departments and freeing employees to perform other vital functions. Other vendors have components of legislated requirements available online or on CD-ROM. However there is no other product that marries regulatory agency mandates with implementation tools, making the latest compliance information immediately available online. No other product provides an interpretative analysis, followed by a practical application tool, therefore providing users with an immediate solution to compliance problems. StayAlert! includes operational components for healthcare organizations, allowing complete facility compliance with mandated requirements, online. |
|
